Combination therapy of BRAF inhibitors for advanced melanoma with BRAF V600 mutation: a systematic review and

Related Experiment Video

Updated: Mar 2, 2026

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

3.4K

Siin Kim1, Hyung Tae Kim1, Hae Sun Suh1

  • 1a College of Pharmacy , Pusan National University , Busandaehak-ro 63 beon-gil, Geumjeong-gu , Busan , South Korea.

The Journal of Dermatological Treatment
|May 16, 2017
PubMed
Abstract

Insights

Combination therapy using BRAF and MEK inhibitors significantly improves outcomes for advanced melanoma patients with BRAF mutations. This approach enhances overall survival and progression-free survival compared to monotherapy.

Area of Science:

  • Oncology
  • Medical Research
  • Clinical Trials

Background:

  • BRAF inhibitors are used for advanced melanoma with BRAF mutations.
  • Acquired resistance necessitates combination strategies for BRAF inhibitors.

Purpose of the Study:

  • To evaluate the efficacy of BRAF inhibitor-based combination therapy in advanced melanoma patients with BRAF mutations.

Main Methods:

  • Systematic review and meta-analysis of comparative studies.
  • Searched MEDLINE, EMBASE, Cochrane Library, and conference proceedings.
  • Employed random-effects inverse variance and Mantel-Haenszel methods for data pooling.

Main Results:

  • Four randomized controlled trials and one cohort study were analyzed.
  • All studies utilized BRAF and MEK inhibitor combinations.
  • Combination therapy showed improved overall survival (HR 0.70) and progression-free survival (HR 0.59).
  • Objective response rate was significantly higher with combination therapy (RR 1.30).

Conclusions:

  • BRAF and MEK inhibitor combination therapy offers significant benefits for advanced melanoma.
  • Improved overall survival, progression-free survival, and objective response rates were observed.
  • This combination strategy is effective for BRAF-mutated advanced melanoma.
Keywords:
Melanomaproto-oncogene proteins B-rafsystematic reviewvemurafenib

More Related Videos

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

9.6K
A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.7K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.3K
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
6.4K